TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03532139
Drug: Enoxaparin + Rosuvastatin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin is an anti-cholesterol medication that is FDA (the U.S. Food and Drug Administration) approved to lower cholesterol and reduce the risk of arterial blood clots. There is evidence that rosuvastatin can lower the risk of venous blood clots in healthy individuals~Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness
Study: NCT00664209
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo therapy
Study: NCT03616886
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
Study: NCT03616886
Drug: MEDI9447
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
Study: NCT03675737
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally BID on Days 1 to 14 Q3W
Study: NCT03396575
Drug: Cyclophosphamide + Fludarabine Lymphodepletive Conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in Group B, however, will receive lymphodepletion with cyclophosphamide + fludarabine after DC vaccination and prior to the intravenous infusion of ex vivo expanded tumor-reactive lymphocytes.
Study: NCT00804375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: cutaneous solution to be applied twice daily for 84 days
Study: NCT01953900
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
Study: NCT04256421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by IV infusion on Day 1 of each 21-day cycle.
Study: NCT02609789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 percent (%) normal saline.
Study: NCT03508700
Drug: TNX-102 SL 5.6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclobenzaprine HCl sublingual tablets
Study: NCT04353778
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo x 8 weeks
Study: NCT03411421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets will be administered.
Study: NCT02564978
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adult participants will be instructed to take their prescribed IP orally two times a day, once in the morning and once in the evening, approximately 12 hours apart. The capsules will be dispensed to the participant in a tight, light-resistant container as defined in the USP in three-month supply aliquots. Starting at Month 9 and continuing at Month 12, a three-month supply will be dispensed to the participant during the study visit or mailed to the participant. Participants will be given an instruction sheet for taking the prescribed IP. Starting at Month 15 participants will receive two bottles for a six-month supply. The IP should be stored between 15-30 degrees C (or 59-86 degrees F).They should be protected from light, moisture, and excessive heat. Participants will be required to bring their bottles of IP to each appropriate visit for capsule counts for compliance monitoring.
Study: NCT03659136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT00237016
Drug: doxycycline treatment
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03462342
Drug: AZD6738
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Cohorts A, B, and C: 160 mg orally once daily for first 7 days of every cycle (Days 1-7 of each 28-day cycle).~Cohort D 1-2: Prescribed higher dose of AZD6738 (120-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated.~Dose Levels 1-3: 120-160 mg twice daily, Days 1-14, in combination with olaparib twice daily, Days 1-28. Alternatively, AZD6738 at 160 mg once daily Days 1-14 with olaparib at 100-150 mg Days 1-28 may be evaluated.~Dose Levels 4-5: Alternative dosing schedule of AZD6738 at 80-160 mg once or twice daily, weekly intermittent schedule (Days 1-5, 8-12, 15-19) in combination with olaparib 100-200 mg twice daily, Days 1-28 may be evaluated. AZD6738 at 160 mg twice daily, Days 1-7 or 240 mg once daily Days 1-14 with olaparib 100-200 mg twice daily Days 1-28 may be evaluated.~Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth.
Study: NCT04068103
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04068103
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04068103
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04068103
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03508232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo in a loading dose of two capsules initially followed by one capsule every 12 hours for 7 days.
Study: NCT03753555
Drug: PCSK9 inhibitor
Normalized name: PCSK9 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 140mg subcutaneously injected, twice each month
Study: NCT03419234
Drug: Antiandrogen Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist
Study: NCT03346200
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised dose of tamoxifen 1 pill/day for 180 days
Study: NCT03997786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Weeks 16 to 52)
Study: NCT01614405
Drug: TDF/FTC/LPV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur
Study: NCT01614405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada.
Study: NCT00968149
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one placebo chewable tablet daily at bed time for 2 weeks
Study: NCT02588443
Drug: RO70097890
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02962284
Drug: abiraterone acetate with Methylprednisolone
Normalized name: Abiraterone Acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: YONSA 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
Study: NCT02454283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01872494
Drug: flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01398267
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: aleglitazar matching placebo orally daily, 4 weeks (Day 15 to Day 43)
Study: NCT02795754
Drug: GSK2838232 IR1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2838232 will be available as film-coated tablet for oral use
Study: NCT02795754
Drug: GSK2838232 IR2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2838232 will be available as film-coated tablet for oral use
Study: NCT02795754
Drug: Placebo PIB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension of hydromellulose acetate succinate will be supplied as powder-in-bottle for reconstitution.
Study: NCT00557284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral granules or chewable tablet, PO QD (given oral daily)
Study: NCT05036837
Drug: OZOPROMAF_SEQ1
Approvals — FDA: no, EMA: no, PMDA: no
Description: OZOPROMAF protocol consists of: local superficial anesthesia by EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (mixture by 26Gx 1⁄2 - 0.45x13mm needle into the mucosal margin surrounding the bone exposure or around the situs already evidenced by CT scan. It is applied on 7-15 days, depending on the patient compliance, until the formation of sequestrum and clinical healing (T1).~Pain intensity is assessed by means of a questionnaire for pain and/or other symptoms evaluation before and after the protocol, based on numerical rating scale (NRS).~After resolution (T1), follow-up visits are scheduled to confirm the healing of MRONJ at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5).~Radiographic evaluations of bone healing are scheduled at T3 and T4.~Positive outcomes for the OZOPROMAF protocol are evaluated at T1 as no clinical signs of acute phlogosis and no symptoms compatible with MRONJ; at T5 as clinical healing and no radiological signs of MRONJ.
Study: NCT04541797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).
Study: NCT02254720
Drug: BEA 2180 BR solution for infusion
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02254720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT02254720
Drug: BEA 2180 BR solution for inhalation
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01574716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02438137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be dispensed during routine study appointments. Placebo will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the placebo with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
Study: NCT00111631
Drug: DPP-IV Inhibitor
Normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses po bid
Study: NCT00111631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po bid
Study: NCT00448552
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02291913
Drug: Toremifine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-estrogen therapy
Study: NCT02132949
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive cyclophosphamide 600 milligrams per square meter (mg/m\^2) intravenous (IV) given on Day 1 of each cycle q2w.
Study: NCT02132949
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive doxorubicin 60 mg/m\^2 IV on Day 1 of each cycle q2w.
Study: NCT03202992
Drug: ABI-1968
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
Study: NCT02917512
Drug: HU00701
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 0.01% + 3% trehalose
Study: NCT02917512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT02056236
Drug: Anti-epileptic drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommendations for the treatment of status epilepticus are based on recent international guidelines for treatment of overt status epilepticus.~The objective of treatment with AED is to suppress all epileptiform activity. There is no clear proof that induction of a burst-suppression pattern is of additional value and induction of burst suppression is therefore not obligate. If the electroencephalographic status epilepticus returns after tapering sedative treatment at 24 hours, the procedure will be repeated. If the status returns after 2 x 24 hours, it will be considered refractory.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented.
Study: NCT04316936
Drug: Dexycu, 9% Intraocular Suspension
Normalized name: Dexycu, 9% intraocular suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexamethasone intraocular suspension
Study: NCT04316936
Drug: Prednisolone Acetate 1%
Normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard postoperative ophthalmic drop regimen
Study: NCT03035084
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule
Study: NCT04593238
Drug: Double Antibiotic paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole and Ciprofloxacin
Study: NCT04593238
Drug: Calcium Hydroxide Paste - Non-Setting
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide paste to be delivered inside the canal as an intra-canal medication
Study: NCT03875313
Drug: CB-839
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.
Study: NCT01939691
Drug: Nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nepafenac 0.1% - NSAID eyedrop
Study: NCT01939691
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisolone acetate 1% - corticosteroid eyedrop
Study: NCT00366249
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis
Study: NCT05768282
Drug: Oral prednisolone (30mg/day) for 28 days
Normalized name: Prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone was started at a dose of 30 mg/day on the third day after RFA, and continued for 4 weeks.
Study: NCT00754065
Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated BAY86-5027 for 28 days per Cycle, for 13 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo
Study: NCT03106922
Drug: PMF104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for oral solution:~* Sachet A: macrogol 4000 52.500 g, anhydrous sodium sulphate 3.750 g, simeticone 0.080 g;~* Sachet B: sodium citrate 1.863 g, anhydrous citric acid 0.813 g, sodium chloride 0.730 g, potassium chloride 0.370 g;~One sachet A + 1 sachet B in 500 ml of water
Study: NCT03658616
Drug: WO3970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of cream to each axilla
Study: NCT03658616
Drug: Placebo (WO3988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of cream to each axilla
Study: NCT02639637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.
Study: NCT01053325
Drug: SP IPT
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with sulphadoxine-pyrimethamine
Study: NCT01505166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 1 x 10\^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
Study: NCT04115423
Drug: Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor Necrosis Factor inhibitors (TNFi) are a group of medicines that suppresses the physiologic response to TNF, a protein involved in early inflammatory events. We will include etanercept, infliximab, adalimumab, and golimumab as TNFis since these drugs are commercialized in Korea.
Study: NCT02446340
Drug: dalazatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
Study: NCT02446340
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
Study: NCT00683800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.
Study: NCT01074294
Drug: OPDC-34712
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPDC-34712 tablets, daily, Orally.
Study: NCT01074294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching-placebo tablets, daily, Orally.
Study: NCT01074294
Drug: Stimulant Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.
Study: NCT02247375
Drug: High dose of BIIL 284 BS tablets
Normalized name: betamethasone 0.284 MG/ML / gentamicin 0.57 MG/ML [Betagen brand of Betamethasone and Gentamicin]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02247375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04278755
Drug: Drospirenone-Ethinyl Estradiol Oral Tablet
Normalized name: drospirenone / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 Mg-0.03 Mg continuous daily Drospirenone-Ethinyl Estradiol.
Study: NCT01798667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of DA-8031, undistinguishable
Study: NCT00112359
Drug: AZLI 75 mg three times a day (TID)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00455650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.
Study: NCT02575924
Drug: sequential medium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of Quinn's Advantage® Fertilization Medium on day0 administration of Quinn's Advantage® Cleavage Medium from day0 to day3 administration of Quinn's Advantage® Blastocyst Medium from day3 to day7
Study: NCT03618758
Drug: mFOLFOX6 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic mFOLFOX6: 5-FU(2400mg/m²), Oxaliplatin(100mg/m²), Leucovorin(100mg/m²)
Study: NCT00312208
Drug: docetaxel, doxorubicin, cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.
Study: NCT00312208
Drug: Docetaxel,doxorubicin, cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
Study: NCT03471585
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: A capsule that contains only dextrose filler administered 2 hours prior to memory testing.
Study: NCT00588471
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
Study: NCT00588471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
Study: NCT02492412
Drug: HE 10
Normalized name: Mycelex Troche 10mg Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002945
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT02620306
Drug: Fimsartan 60mg~120mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.